Badenes Rafael, Hutton Brian, Citerio Giuseppe, Robba Chiara, Aguilar Gerardo, Alonso-Arroyo Adolfo, Taccone Fabio Silvio, Tornero Carlos, Catalá-López Ferrán
Department of Anesthesiology and Surgical-Trauma Intensive Care, Hospital Clinic Universitari de València, University of Valencia, Valencia, Spain.
Department of Surgery, Faculty of Medicine, University of Valencia, Valencia, Spain.
BMJ Open. 2020 Feb 6;10(2):e033913. doi: 10.1136/bmjopen-2019-033913.
Acute brain injury is a challenging public health problem worldwide. Elevated intracranial pressure is a common complication after acute brain injury. Hyperosmolar therapy is one of the main therapeutic strategies for the management of intracranial hypertension. This study protocol outlines an umbrella review of meta-analyses which will investigate the benefits and harms of hyperosmolar therapy routinely used for the management of acute brain injury in the intensive care.
We will search PubMed/MEDLINE, EMBASE and the Cochrane Database of Systematic Reviews. We will include meta-analyses of primary research studies (eg, randomised controlled trials, observational studies or both) that evaluate one or more hyperosmolar solutions (including hypertonic saline and/or mannitol) for the treatment of adult patients with acute brain injury of any severity. Two researchers will independently screen all citations, full-text articles and abstract data. Potential conflicts will be resolved through discussion with a third researcher. Primary outcomes will be mortality and neurological outcomes at discharge. Secondary outcomes will include control of intracranial pressure, cerebral perfusion pressure, length of stay (in hospital an intensive care unit) and any adverse event. Quality of the included meta-analyses will be assessed using the AMSTAR-2 tool. An overall summary of methods and results will be performed using tabular and graphical approaches and will be supplemented by narrative description. We will analyse whether published meta-analyses present an outline of available evidence (eg, cited, described and discussed any previous meta-analysis). Where objectives from two or more meta-analyses overlap, we will assess the causes of any noted discrepancies between meta-analyses.
No ethical approval will be required. Findings from this study will be published in a peer-reviewed journal. All data will be deposited in a cross-disciplinary public repository.
CRD42019148152.
急性脑损伤是全球范围内一个具有挑战性的公共卫生问题。颅内压升高是急性脑损伤后的常见并发症。高渗疗法是治疗颅内高压的主要治疗策略之一。本研究方案概述了一项伞状综述,该综述将调查在重症监护中常规用于治疗急性脑损伤的高渗疗法的益处和危害。
我们将检索PubMed/MEDLINE、EMBASE和Cochrane系统评价数据库。我们将纳入对一项或多项高渗溶液(包括高渗盐水和/或甘露醇)治疗任何严重程度的成年急性脑损伤患者的原发性研究(如随机对照试验、观察性研究或两者皆有)的荟萃分析。两名研究人员将独立筛选所有文献引用、全文文章和摘要数据。潜在的冲突将通过与第三名研究人员讨论来解决。主要结局将是出院时的死亡率和神经学结局。次要结局将包括颅内压控制、脑灌注压、住院时间(在医院和重症监护病房)以及任何不良事件。将使用AMSTAR-2工具评估纳入的荟萃分析的质量。将使用表格和图形方法对方法和结果进行总体总结,并辅以叙述性描述。我们将分析已发表的荟萃分析是否呈现了现有证据的概述(例如,引用、描述和讨论了之前的任何荟萃分析)。如果两项或多项荟萃分析的目标重叠,我们将评估荟萃分析之间任何显著差异的原因。
无需伦理批准。本研究的结果将发表在同行评审期刊上。所有数据将存入跨学科公共知识库。
PROSPERO注册号:CRD42019148152。